Enlivex Ltd. ENLV
Set alert
1.78 USD -0.76 -29.92%
At close · Oct 30
1.79 +0.01 +0.56%
After hours · Oct 30, 7:30 PM ET
1.73 Day range 2.47
0.173 52-week range 18.15
- YTD
- -83.13%
- 1 year
- -88.70%
- Open
- 2.47
- Prev close
- 2.54
- Mkt cap
- 2.73M
- Vol
- 128.30K
- Avg vol
- 65.51K
- EPS
- 7,904.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.73
- High
- 2.47
- Forward P/E
- -2.14
- Beta
- 1.10
- Short ratio
- 0.56
- Inst. own
- 18.81%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.27
- 200-d avg
- 1.67
- 1y target
- 9.50
2Y chart
Events in this range
- Nov 14, 2024Rating: D. Boral Capital · Buy → Buy
- Nov 29, 2024Earnings: -0.12; estimate -0.16; surprise 25%
- Dec 3, 2024Rating: D. Boral Capital · Buy → Buy
- Dec 11, 2024Rating: D. Boral Capital · Buy → Buy
- Jul 9, 2026Split: 1 for 15
Signals (93)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| RSI: Overbought | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| RSI: Oversold | Jun 30, 2026 | 4 months ago |
| RSI: Oversold | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 4, 2026 | 5 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | May 1, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 22, 2026 | 6 months ago |
| SMA: Bearish | Mar 27, 2026 | 7 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 26, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 25, 2026 | 7 months ago |
| SMA: Bullish | Mar 23, 2026 | 7 months ago |
| SMA: Bullish | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 20, 2026 | 7 months ago |
| SMA: Bearish | Mar 19, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 5, 2026 | 8 months ago |
| MACD: Buy Signal | Mar 4, 2026 | 8 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 19, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 12, 2026 | 8 months ago |
| SMA: Bullish | Feb 3, 2026 | 9 months ago |
| SMA: Bearish | Jan 29, 2026 | 9 months ago |
| RSI: Overbought | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 23, 2026 | 9 months ago |
| SMA: Bullish | Jan 14, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| SMA: Bullish | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 6, 2026 | 9 months ago |
| RSI: Oversold | Dec 30, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 12, 2025 | 10 months ago |
| SMA: Bearish | Dec 9, 2025 | 10 months ago |
| SMA: Bearish | Dec 9, 2025 | 10 months ago |
| SMA: Bullish | Dec 3, 2025 | 11 months ago |
| SMA: Bullish | Dec 3, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 2, 2025 | 11 months ago |
| RSI: Oversold | Nov 20, 2025 | 11 months ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Oct 15, 2025 | 1 year ago |
| SMA: Bullish | Oct 14, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 10, 2025 | 1 year ago |
| SMA: Bullish | Oct 9, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 19, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 19, 2025 | 1 year ago |
| RSI: Overbought | Aug 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 29, 2025 | 1 year ago |
| RSI: Overbought | Jul 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 17, 2025 | 1 year ago |
| RSI: Overbought | Jul 10, 2025 | 1 year ago |
| RSI: Overbought | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 16, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 16, 2025 | 1 year ago |
| SMA: Bearish | May 28, 2025 | 1 year ago |
| SMA: Bullish | May 27, 2025 | 1 year ago |
| SMA: Bearish | May 16, 2025 | 1 year ago |
| MACD: Sell Signal | May 16, 2025 | 1 year ago |
| SMA: Bullish | May 14, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| SMA: Bullish | Apr 28, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 23, 2025 | 1 year ago |
| SMA: Bearish | Mar 20, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| SMA: Bullish | Mar 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 13, 2025 | 1 year ago |
| SMA: Bullish | Mar 5, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| SMA: Bullish | Feb 28, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 24, 2025 | 1 year ago |
| SMA: Bullish | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 31, 2024 | 1 year ago |
Key statistics
- Market cap
- 27.27M
- Enterprise value
- -1.30M
- Trailing P/E
- 0.00
- Forward P/E
- -2.14
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.77
- EPS (TTM)
- -0.98
- Beta
- 1.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -11.98M
- Total cash
- 25.94M
- Total debt
- 835.00K
- Return on equity
- -61.17%
- Shares outstanding
- 21.99M
- Short % of float
- 0.49%
- 50-day average
- 1.27
- 200-day average
- 1.67
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 9.50 +433.7% upside
Now 1.78
- Target (low)
- 6.00
- Target (mean)
- 9.50
- Target (high)
- 13.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.16.
Financials — quick view
ENLV Revenue — quarterly 0
ENLV Net income — quarterly 1.89B
ENLV EPS — quarterly 1,830.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 29, 2024 | Sep 1, 2024 | -0.16 | -0.12 | +0.04 | +25.00% |
| Aug 30, 2024 | Jun 1, 2024 | -0.22 | -0.16 | +0.06 | +27.27% |
| Jun 14, 2024 | Mar 1, 2024 | -0.25 | -0.22 | +0.03 | +12.00% |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -0.48 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.32 | -0.32 | 0.00 | 0.00% |
| Sep 1, 2023 | Jun 1, 2023 | -0.43 | -0.37 | +0.06 | +13.95% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | D. Boral Capital | main | Buy | Buy |
| Dec 3, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 14, 2024 | D. Boral Capital | main | Buy | Buy |
| Sep 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 26, 2024 | EF Hutton | main | Buy | Buy |
| Sep 24, 2024 | EF Hutton | main | Buy | Buy |
About Enlivex Ltd.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- enlivex.com
News
- Enlivex Reports 135 Of 182 Planned Patients Randomized And Dosed In Phase 2b Knee Osteoarthritis Trial Of Allocetra; Topline Six-Month Data Expected By Mid-2027
- Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
- Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
- Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
- Enlivex Reveals 1-For-16 Reverse Share Split To be Effective October 27, 2026
- Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Enlivex Launches Cost Reduction Plan To Prioritize Phase 2b Allocetra Knee Osteoarthritis Trial, Topline Data Expected By Mid-2027
- Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
- 12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on ENLV — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 11.52% | 2,139,000 | 2.65M | Sep 29, 2024 |
| Morgan Stanley | 1.32% | 245,754 | 304.73K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.40% | 74,789 | 92.74K | Sep 29, 2024 |
| Sigma Investment Counselors Inc | 0.16% | 30,000 | 37.20K | Sep 29, 2024 |
| Xtx Topco Ltd | 0.12% | 22,659 | 28.10K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.08% | 13,935 | 17.28K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.06% | 10,420 | 12.92K | Oct 30, 2024 |